基线前列腺萎缩范围与重复活检中低级别和高级别前列腺癌发生率较低相关
在度他雄胺减少前列腺癌事件试验安慰剂组中,对3165名50-75岁、前列腺特异性抗原2.5-10 ng/mL且既往活检阴性、接受2年重复活检的男性进行回顾性分析。基线前列腺萎缩范围越大,2年活检阳性风险越低,且呈剂量依赖性,并与低级别(Gleason 2-6)和高级别(Gleason 7-10)前列腺癌发生率较低相关。
要点
- 基线前列腺萎缩范围越大,2年重复活检检出前列腺癌的风险越低,且呈剂量依赖性。
- 与无萎缩者相比,萎缩累及1%-25%、26%-50%、51%-75%和>75%核心的比值比分别为0.65、0.60、0.56和0.35。
- 更广泛的前列腺萎缩与低级别(Gleason 2-6)和高级别(Gleason 7-10)前列腺癌发生率较低均相关。
核心结论
- 基线前列腺萎缩范围与较低的前列腺癌风险独立相关,且呈剂量依赖性。
研究设计与样本
- 对度他雄胺减少前列腺癌事件试验安慰剂组中3165名50-75岁、前列腺特异性抗原2.5-10 ng/mL、既往活检阴性并接受2年重复活检的男性进行回顾性分析。
- 前列腺萎缩范围定义为具有萎缩改变的核心百分比。
- 采用单因素和多因素logistic回归评估基线前列腺萎缩与2年活检阳性的关联,并控制基线协变量。
主要发现
- 基线核心萎缩累及无、1%-25%、26%-50%、51%-75%和>75%者分别为966/3165(30.5%)、1189/3165(37.6%)、677/3165(21.4%)、209/3165(6.6%)和124/3165(3.9%)。
- 更广泛的前列腺萎缩与年龄较大、前列腺特异性抗原较低、前列腺体积较大以及急性和慢性炎症患病率较高相关(所有P < .05)。
- 与无前列腺萎缩者相比,核心累及1%-25%、26%-50%、51%-75%和>75%者的前列腺癌比值比分别为0.65(95%置信区间[CI] = 0.52-0.81)、0.60(95% CI = 0.46-0.78)、0.56(95% CI = 0.37-0.86)和0.35(95% CI = 0.19-0.67)。
- 多因素分析中,前列腺萎缩范围与较低的前列腺癌风险独立相关(P < .001)。
- 更广泛的前列腺萎缩与低级别(Gleason 2-6)和高级别(Gleason 7-10)前列腺癌发生率较低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether baseline prostate atrophy (PA) extent is associated with prostate cancer (PCa) incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies. MATERIALS AND METHODS: We performed a retrospective analysis of 3165 men 50-75 years old with prostate-specific antigen between 2.5 and 10 ng/mL and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events trial who underwent a 2-year repeat biopsy. PA extent was defined as the percentage of cores with atrophic changes. The association of baseline PA with positive 2-year biopsies was evaluated with logistic regression in uni- and multivariable analysis, controlling for baseline covariates. RESULTS: PA involving none, 1%-25%, 26%-50%, 51%-75%, and >75% of the baseline cores was observed in 966 of 3165 (30.5%), 1189 of 3165 (37.6%), 677 of 3165 (21.4%), 209 of 3165(6.6%), and 124 of 3165 (3.9%) cases, respectively. More extensive PA was associated with older age, lower prostate-specific antigen, larger prostate volume, and higher prevalence of acute and chronic inflammations (all P < .05). Compared to subjects without PA, those with 1%-25%, 26%-50%, 51%-75%, and >75% core involvement had an odds ratio for PCa of 0.65 (95% confidence interval [CI] = 0.52-0.81), 0.60 (95% CI = 0.46-0.78), 0.56 (95% CI = 0.37-0.86), and 0.35 (95% CI = 0.19-0.67), respectively. In multivariable analysis, the extent of PA was independently associated with lower PCa risk (P < .001). More extensive PA was associated with lower incidence of low-grade (Gleason 2-6) and high-grade (Gleason 7-10) PCa. CONCLUSION: The extent of baseline PA is independently associated with lower PCa risk in a dose-dependent fashion.
引用
- Freitas DM, Andriole GL, Castro-Santamaria R, et al. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy. Urology. 2016. PMID: 28024967. doi:10.1016/j.urology.2016.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。